Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease
Dereje A. Negatu, Matthew Zimmerman, Véronique Dartois, Thomas Dick
Abstract
against Mycobacterium abscessus with and without the bioactive form of the oral β-lactamase inhibitor avibactam ARX1796. Sulopenem was equally active without avibactam, while tebipenem, cefuroxime, and amoxicillin required avibactam for optimal activity. Systematic pairwise combination of the four β-lactams revealed strong bactericidal synergy for each of sulopenem, tebipenem, and cefuroxime combined with amoxicillin in the presence of avibactam. These all-oral β-lactam combinations warrant clinical evaluation.
Topics & Concepts
Mycobacterium abscessusMicrobiologyLactamLung diseaseMedicineAntibacterial agentAntibioticsBeta-lactamMycobacteriumLungBiologyChemistryTuberculosisInternal medicinePathologyStereochemistryMycobacterium research and diagnosisTuberculosis Research and EpidemiologyInfectious Diseases and Mycology